Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 12
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 13
Merger 14
OphthaliX Merges with Wize Pharma 14
Licensing Agreements 15
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 15
Equity Offering 16
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 16
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 17
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 18
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 19
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 20
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 21
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 23
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 24
OphthaliX Withdraws Public Offering of Shares for USD10 Million 25
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 26
Denali Concrete Completes Private Placement Of Shares For Above US$6 Million 27
Acquisition 28
Denali Concrete Acquires EyeFite From Can-Fite BioPharma 28
Can-Fite BioPharma Ltd – Key Competitors 29
Can-Fite BioPharma Ltd – Key Employees 30
Can-Fite BioPharma Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 27, 2017: Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update 32
Sep 01, 2017: Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update 35
May 30, 2017: Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update 37
Mar 31, 2017: Can-Fite Reports 2016 Financial Results & Provides Clinical Update 39
Nov 25, 2016: Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update 41
Aug 26, 2016: Can-Fite Reports Financial Results for Six Months Ended June 30, 2016 43
May 27, 2016: Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update 45
Apr 01, 2016: Can-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update 47
Research And Development 49
Jun 05, 2017: Can-Fite BioPharma establishes clinical advisory board for NAFLD and NASH treatment 49
Product News 50
08/08/2016: Can-Fites Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology 50
01/11/2016: Can-Fite Announces Update on CF101 51
01/11/2016: Can-Fite Announces Update on CF102 52
Clinical Trials 53
Oct 13, 2016: Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH 53
Sep 13, 2016: Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial 54
Jul 25, 2016: Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD 55
Jul 05, 2016: OphthaliX Announces Phase II Glaucoma Data 56
Jun 15, 2016: Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects 57
Jun 07, 2016: Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) 58
Jun 01, 2016: Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis 59
Mar 17, 2016: Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis 60
Jan 05, 2016: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 12
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 13
OphthaliX Merges with Wize Pharma 14
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 15
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 16
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 17
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 18
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 19
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 20
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 21
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 23
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 24
OphthaliX Withdraws Public Offering of Shares for USD10 Million 25
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 26
Denali Concrete Completes Private Placement Of Shares For Above US$6 Million 27
Denali Concrete Acquires EyeFite From Can-Fite BioPharma 28
Can-Fite BioPharma Ltd, Key Competitors 29
Can-Fite BioPharma Ltd, Key Employees 30
Can-Fite BioPharma Ltd, Other Locations 31
Can-Fite BioPharma Ltd, Subsidiaries 31